# Evaluating the Safety and Immune Response to Three Different Prime-Boost HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults

> **NCT01970449** · PHASE1 · WITHDRAWN · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)**

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** DNA Nat-B env vaccine
- **BIOLOGICAL:** NYVAC Nat-B env vaccine
- **BIOLOGICAL:** DNA CON-S env vaccine
- **BIOLOGICAL:** NYVAC CON-S env vaccine
- **BIOLOGICAL:** DNA Mosaic env vaccine
- **BIOLOGICAL:** NYVAC Mosaic env vaccine
- **BIOLOGICAL:** Placebo
- **DEVICE:** Biojector 2000® Needle-Free Injection Management System™ (Biojector 2000®)

## Key facts

- **NCT ID:** NCT01970449
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2018-08
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2021-10-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01970449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01970449, "Evaluating the Safety and Immune Response to Three Different Prime-Boost HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01970449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*